{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:45:59Z","timestamp":1787741159452,"version":"build-2784847793"},"reference-count":40,"publisher":"Elsevier BV","issue":"23","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,4,21]],"date-time":"2014-04-21T00:00:00Z","timestamp":1398038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"European Union FP7 Industry"},{"name":"Academia Partnerships and Pathways award"},{"name":"Novartis Vaccines Institute for Global Health"},{"name":"Swiss Tropical and Public Health Institute"},{"name":"Kenyan Medical Research Institute"},{"name":"Wellcome Trust Sanger Institute","award":["251522"],"award-info":[{"award-number":["251522"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.vaccine.2014.03.068","type":"journal-article","created":{"date-parts":[[2014,4,3]],"date-time":"2014-04-03T08:15:19Z","timestamp":1396512919000},"page":"2688-2695","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"title":["A broadly-protective vaccine against meningococcal disease in sub-Saharan Africa based on Generalized Modules for Membrane Antigens (GMMA)"],"prefix":"10.1016","volume":"32","author":[{"given":"Oliver","family":"Koeberling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Ispasanie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Pluschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique A.","family":"Caugant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Saul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9694-0846","authenticated-orcid":false,"given":"Calman A.","family":"MacLennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2014.03.068_bib0005","doi-asserted-by":"crossref","first-page":"B26","DOI":"10.1016\/j.vaccine.2011.12.032","article-title":"The changing and dynamic epidemiology of meningococcal disease","volume":"30","author":"Halperin","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.03.068_bib0010","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1377\/hlthaff.2011.0328","article-title":"Eliminating epidemic Group A meningococcal meningitis in Africa through a new vaccine","volume":"30","author":"Laforce","year":"2011","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.vaccine.2014.03.068_bib0015","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1016\/j.vaccine.2013.04.036","article-title":"Emergence of serogroup X meningococcal disease in Africa: need for a vaccine","volume":"31","author":"Xie","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.03.068_bib0020","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.3201\/eid1609.100510","article-title":"Increase in Neisseria meningitidis serogroup W135, Niger, 2010","volume":"16","author":"Collard","year":"2010","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2014.03.068_bib0025","doi-asserted-by":"crossref","first-page":"e19513","DOI":"10.1371\/journal.pone.0019513","article-title":"Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso","volume":"6","author":"Delrieu","year":"2011","journal-title":"PLoS One"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2014.03.068_bib0030","doi-asserted-by":"crossref","first-page":"B13","DOI":"10.1016\/j.vaccine.2009.04.062","article-title":"Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution","volume":"27","author":"Marc","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.03.068_bib0035","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(13)61612-8","article-title":"Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected]","volume":"383","author":"Daugla","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2014.03.068_bib0040","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1186\/1471-2334-13-363","article-title":"Phenotypic and genotypic characterization of meningococcal carriage and disease isolates in Burkina Faso after mass vaccination with a serogroup a conjugate vaccine","volume":"13","author":"Kristiansen","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2014.03.068_bib0045","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/cid\/cis892","article-title":"Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity","volume":"56","author":"Kristiansen","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2014.03.068_bib0050","doi-asserted-by":"crossref","first-page":"e35616","DOI":"10.1371\/journal.pone.0035616","article-title":"High yield production process for Shigella outer membrane particles","volume":"7","author":"Berlanda","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2014.03.068_bib0055","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1084\/jem.20021911","article-title":"Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870","volume":"197","author":"Masignani","year":"2003","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2014.03.068_bib0060","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1099\/mic.0.029876-0","article-title":"The modular architecture of meningococcal factor H-binding protein","volume":"155","author":"Beernink","year":"2009","journal-title":"Microbiology"},{"key":"10.1016\/j.vaccine.2014.03.068_bib0065","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/j.vaccine.2009.12.027","article-title":"Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates","volume":"28","author":"Pajon","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.03.068_bib0070","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1001\/jama.281.16.1520","article-title":"Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile","volume":"281","author":"Tappero","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2014.03.068_bib0075","doi-asserted-by":"crossref","first-page":"e1302","DOI":"10.1371\/journal.pntd.0001302","article-title":"Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development","volume":"5","author":"Pajon","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2014.03.068_bib0080","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/2049-632X.12000","article-title":"Lack of antigenic diversification of major outer membrane proteins during clonal waves of Neisseria meningitidis serogroup A colonization and disease","volume":"67","author":"Huber","year":"2013","journal-title":"Pathog Dis"},{"key":"10.1016\/j.vaccine.2014.03.068_bib0085","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1002\/pmic.200500164","article-title":"Outer membrane vesicles from group B Neisseria meningitidis delta gna33 mutant: proteomic and immunological comparison with detergent-derived outer membrane vesicles","volume":"6","author":"Ferrari","year":"2006","journal-title":"Proteomics"},{"key":"10.1016\/j.vaccine.2014.03.068_bib0090","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1074\/mcp.M700295-MCP200","article-title":"Proteomics characterization of outer membrane vesicles from the extraintestinal pathogenic Escherichia coli DeltatolR IHE3034 mutant","volume":"7","author":"Berlanda","year":"2008","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.vaccine.2014.03.068_bib0095","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.resmic.2004.04.007","article-title":"Improved methods for producing outer membrane vesicles in Gram-negative bacteria","volume":"155","author":"Henry","year":"2004","journal-title":"Res Microbiol"},{"key":"10.1016\/j.vaccine.2014.03.068_bib0100","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1016\/j.vaccine.2010.04.082","article-title":"Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process","volume":"28","author":"van de Waterbeemd","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.03.068_bib0105","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1111\/j.1365-2958.2003.03903.x","article-title":"Structure of the OmpA-like domain of RmpM from Neisseria meningitidis","volume":"51","author":"Grizot","year":"2004","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.vaccine.2014.03.068_bib0110","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1111\/j.1365-3156.2005.01520.x","article-title":"Emergence of W135 meningococcal meningitis in Ghana","volume":"10","author":"Forgor","year":"2005","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.vaccine.2014.03.068_bib0115","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1128\/JB.187.10.3421-3430.2005","article-title":"CrgA is an inducible LysR-type regulator of Neisseria meningitidis, acting both as a repressor and as an activator of gene transcription","volume":"187","author":"Ieva","year":"2005","journal-title":"J Bacteriol"},{"key":"10.1016\/j.vaccine.2014.03.068_bib0120","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1086\/589308","article-title":"Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin","volume":"198","author":"Koeberling","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.03.068_bib0125","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1128\/IAI.72.4.1914-1919.2004","article-title":"GNA33 of Neisseria meningitidis is a lipoprotein required for cell separation, membrane architecture, and virulence","volume":"72","author":"Adu-Bobie","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2014.03.068_bib0130","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1086\/432102","article-title":"Protective antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed genome-derived neisserial antigen 1870","volume":"192","author":"Hou","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.03.068_bib0135","unstructured":"Egen RC, Fortin LA, Sun WWQ. Animal component free meningococcal polysaccharide fermentation and seedbank development. Patent No. US 7,399,615 B2; 2008."},{"key":"10.1016\/j.vaccine.2014.03.068_bib0140","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1128\/CVI.00103-10","article-title":"Impaired immunogenicity of a meningococcal factor H-binding protein vaccine engineered to eliminate factor h binding","volume":"17","author":"Beernink","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2014.03.068_bib0145","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3201\/eid1502.080988","article-title":"Serogroup W135 meningococcal meningitis, Northern Cameroon, 2007-2008","volume":"15","author":"Massenet","year":"2009","journal-title":"Emerg Infect Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2014.03.068_bib0150","doi-asserted-by":"crossref","first-page":"A37","DOI":"10.1016\/j.vaccine.2007.04.038","article-title":"The first large epidemic of meningococcal disease caused by serogroup W135, Burkina Faso, 2002","volume":"25","author":"Koumare","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.03.068_bib0155","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1086\/511646","article-title":"Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger","volume":"44","author":"Boisier","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2014.03.068_bib0160","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1086\/339010","article-title":"Prospective study of a serogroup X Neisseria meningitidis outbreak in northern Ghana","volume":"185","author":"Gagneux","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.03.068_bib0200","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1016\/j.vaccine.2010.05.006","article-title":"Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine","volume":"28","author":"Zollinger","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.03.068_bib0165","doi-asserted-by":"crossref","first-page":"e66536","DOI":"10.1371\/journal.pone.0066536","article-title":"Mutant native outer membrane vesicles combined with a serogroup A polysaccharide conjugate vaccine for prevention of meningococcal epidemics in Africa","volume":"8","author":"Pajon","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2014.03.068_bib0170","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1128\/CVI.00542-10","article-title":"A critical threshold of meningococcal factor H binding protein expression is required for increased breadth of protective antibodies elicited by native outer membrane vesicle vaccines","volume":"18","author":"Koeberling","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2014.03.068_bib0175","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1128\/CVI.00403-08","article-title":"Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2","volume":"16","author":"Koeberling","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2014.03.068_bib0180","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1086\/597806","article-title":"Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa","volume":"199","author":"Beernink","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.03.068_bib0185","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.4049\/jimmunol.1003470","article-title":"A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination","volume":"186","author":"Beernink","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2014.03.068_bib0190","doi-asserted-by":"crossref","first-page":"e1002688","DOI":"10.1371\/journal.ppat.1002688","article-title":"The effect of human factor H on immunogenicity of meningococcal native outer membrane vesicle vaccines with over-expressed factor H binding protein","volume":"8","author":"Beernink","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2014.03.068_bib0195","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1128\/IAI.65.10.4022-4029.1997","article-title":"Complement factor C3 deposition and serum resistance in isogenic capsule and lipooligosaccharide sialic acid mutants of serogroup B Neisseria meningitidis","volume":"65","author":"Vogel","year":"1997","journal-title":"Infect Immun"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14004496?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14004496?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T05:10:51Z","timestamp":1597641051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X14004496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":40,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0264410X14004496"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.03.068","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A broadly-protective vaccine against meningococcal disease in sub-Saharan Africa based on Generalized Modules for Membrane Antigens (GMMA)","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.03.068","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}